EUVIMEDEUVIMED entdecken
Crossref

Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma

Hiroki Ishihara iD, Koichi Nishimura, Yuki Nemoto, Shinsuke Mizoguchi, Takayuki Nakayama, Hironori Fukuda, Hiroaki Shimmura, Yasunobu Hashimoto, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi iD

Geriatrics & Gerontology International · 2025-08 · 25 (8) · 1082-1088

DOI: 10.1111/ggi.70105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Geriatrics & Gerontology International, online erschienen am 18.06.2025. Verfasst von Hiroki Ishihara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To clarify the association between age and treatment outcomes of first‐line immune checkpoint inhibitor (ICI) combination therapy for previously untreated advanced renal cell carcinoma (RCC).

Methods

We retrospectively evaluated the clinical data of 246 patients who received ICI combination therapy as a first‐line systemic therapy for advanced RCC. The patients were divided into three groups based on age as follows: Age I, ≤ 65 years; Age II, > 65 to ≤ 75 years; and Age III, > 75 years. Survival, tumor response, and toxicity were compared among the three groups.

Results

Of 246 patients, 111 (45%) were treated with ICI dual combination therapy. In them, progression‐free survival, overall survival, and objective response rate were not significantly different among age‐based subgroups ( P > 0.05). The development rates of adverse events of any grade and those of grade ≥3 and the rates of treatment interruption, discontinuation, and glucocorticoid use were not significantly different among the groups ( P > 0.05). In the remaining 135 patients (55%) receiving combinations of ICIs with tyrosine kinase inhibitors, similar findings were observed: the survival, tumor response, and toxicity profiles were comparable among age‐based subgroups ( P > 0.05).

Conclusion

The effectiveness and safety profiles of first‐line ICI combination therapy did not deteriorate, even in older patients. These findings suggest that ICI combination therapy for RCC should not be avoided because of chronological age alone. Geriatr Gerontol Int 2025; 25: 1082–1088 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedFemaleRetrospective StudiesMiddle AgedAge FactorsTreatment OutcomeAged, 80 and overAdult

Stichwörter der Autor:innen

IOTKIimmuno‐oncologyipilimumablenvatinib

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan.
  • Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Japan.
  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Adachi-ku, Japan.
  • Department of Urology, Jyoban Hospital, Iwaki, Japan.
  • Department of Urology, Saiseikai Kazo Hospital, Kazo, Japan.

ORCID-Profile: Hiroki Ishihara, Toshio Takagi

Zitieren

APA

Ishihara, H., Nishimura, K., Nemoto, Y., Mizoguchi, S., Nakayama, T., Fukuda, H., Shimmura, H., Hashimoto, Y., Yoshida, K., Iizuka, J., Kondo, T., & Takagi, T. (2025). Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. Geriatrics & Gerontology International, 25(8), 1082-1088. https://doi.org/10.1111/ggi.70105

Vancouver

Ishihara H, Nishimura K, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, et al. Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. Geriatrics & Gerontology International. 2025;25(8):1082-1088. doi:10.1111/ggi.70105

BibTeX
@article{Ishihara2025,
  author = {Ishihara, Hiroki and Nishimura, Koichi and Nemoto, Yuki and Mizoguchi, Shinsuke and Nakayama, Takayuki and Fukuda, Hironori and Shimmura, Hiroaki and Hashimoto, Yasunobu and Yoshida, Kazuhiko and Iizuka, Junpei and Kondo, Tsunenori and Takagi, Toshio},
  title = {Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma},
  journal = {Geriatrics & Gerontology International},
  year = {2025},
  volume = {25},
  number = {8},
  pages = {1082--1088},
  doi = {10.1111/ggi.70105}
}
Kostenlos starten →